Previous 10 | Next 10 |
ANAHEIM, CA, April 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it is offering free access to the UnCraveRxȒ...
Anaheim, CA - ( NewMediaWire ) - April 10, 2020 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it is offering free access to the UnCraveRx™ App for a limited...
ANAHEIM, CA, April 07, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today announced that it is offering substance use disorder (SUD) medic...
Kiniksa Pharmaceuticals (NASDAQ: KNSA ) announces "early evidence" of treatment response in COVID-19-related pneumonia and hyperinflammation with antibody mavrilimumab. Shares up 42% premarket. More news on: Kiniksa Pharmaceuticals, Ltd., Vaccinex, Inc., BioCorRx Inc., Health...
ANAHEIM, CA, March 31, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update and reported on recent corporate deve...
ANAHEIM, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, has been awarded an additional $2.8 million. This is the second tranche ...
ANAHEIM, CA, Dec. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2019 and reported on recen...
Ultra-thinly traded nano cap BioCorRx ( OTCQB:BICX +7.7% ) is up, albeit on only 700 shares, in reaction to encouraging preclinical data on VDM-001, its candidate for the reversal of opioid overdose that it says is an alternative to naloxone. More news on: BioCorRx Inc., Aurobindo Phar...
Early preclinical data suggests VDM-001 may prevent overdose from fentanyl ANAHEIM, CA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a leader, developer and provider of advanced solutions in the treatment of addictio...
Early preclinical data suggests VDM-001 may prevent overdose from fentanyl Anaheim, CA - ( NewMediaWire ) - December 03, 2019 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a leader, developer and provider of advanced solutions in the treatment of addiction and relat...
News, Short Squeeze, Breakout and More Instantly...
ANAHEIM, CA - ( NewMediaWire ) - May 16, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended March 31, 2024, and...
ANAHEIM, CA - ( NewMediaWire ) - April 03, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer of innovative treatment programs for substance use and related disorders, today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmace...
ANAHEIM, CA - ( NewMediaWire ) - April 02, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on...